Early Access Program of Lazertinib in Republic of Korea

Sponsor
Yuhan Corporation
Study ID
NCT04829422
Status
Approved For Marketing

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lazertinib 240 mg — DRUG
    The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances

Study Details

This early access program will be conducted to provide access to Lazertinib for adult patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with T790M mutation-positive after 1st/2nd generation EGFR TKIs Therapy.

Key Dates

Status verified
Feb 2022

Related Studies